Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: A systematic review and meta-analysis

South African Medical Journal

Volumn 102, Issue 11, 2012, Pages 855-859

  Bera, Ebrahim ^a   Mia, Rafiq ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); DEATH; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; LIVER TOXICITY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PREGNANT WOMAN; RISK; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; NEVIRAPINE; PATIENT SELECTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84868271194     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.5700     Document Type: Article

References (44)

1. United States Food and Drug Administration (FDA). FDA Advisory on nevirapine. AIDS Treat News 2005;2205(409):7.
2. FDA. Center for Drug Evaluation and Research. Rockville, USA: FDA, 2011. http://www.accessdata. fda.gov/drugsatfda_docs/label/2011/020636s039_020933s030lbl.pdf (accessed 13 December 2011).
3. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004;35(5):538-539.
4. Kondo W, Carraro EA, Prandel E, et al. Nevirapine-induced side-effects in pregnant women-experience of a Brazilian University hospital. Braz J Infect Dis 2007;11(6):544-548.
5. Marazzi MC, Germano P, Liotta G, et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med 2006;7:338-344. [http://dx.doi.org/10.1111/j.1468-1293.2006.00386.x]
6. Ouyang DW, Brogly SB, Lu M, et al. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS 2010;24(1):109-114. [http://dx.doi. org/10.1097/QAD.0b013e3283323941]
7. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants. Recommendations for a public health approach-2010 version. Geneva, Switzerland: WHO, 2010.
8. WHO. Summary of available safety data for nevirapine, stavudine, zidovudine and tenofovir. Geneva, Switzerland: WHO, 2009. http://www.who.int/hiv/topics/treatment/neveriapine_stavudine_ zidovudine_tenofovir.pdf (accessed 21 November 2011).
9. Department of Health. Clinical Guidelines: PMTCT 2010. Pretoria: Department of Health, 2010.
10. Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. September 14, 2011. Available at: http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf. Accessed November 2011.
11. de Ruiter A, Taylor GP, Palfreeman A, et al. British HIV Association Guidelines for the management of HIV infection in pregnant women 2012. Consultation draft. http://www.bhiva.org/documents/ Guidelines/Pregnancy/Pregnancy_Guidelines_for_Consultation120125.pdf (accessed 24 February 2012).
12. Liberati A, Altmann DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700. [http://dx.doi.org/10.1136/bmj.b2700]
13. National Institutes of Health. Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda, USA: NIH, 2004. http://www.niaid.nih.gov/labsandresources/resources/ daidsclinrsrch/documents/daidsaegradingtable.pdf (accessed 21 November 2011).
14. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558. [http://dx.doi.org/10.1002/sim.1186]
15. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS 2006;20(10):1419-1427. [http://dx.doi.org/10.1097/01. aids.0000233576.33973.b3]
16. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of motherto-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008;22(8):973-981. [http://dx.doi.org/10.1097/QAD.0b013e3282f9b67a]
17. Bersoff-Matcha SJ, Rourke D, Blank J. Evaluation of the safety of nevirapine during pregnancy. J Acquir Immune Defic Syndr 2010;54(5):560-562. [http://dx.doi.org/10.1097/QAI.0b013e3181d36024]
18. Black V, Hoffman RM, Sugar CA, et al. Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2008;49(3):276-281. [http://dx.doi.org/10.1097QAI.0b013e318189a769]
19. Bottaro EG, Huberman MJ, Iannella M del Carmen, et al. Nevirapine-associated toxicity in clinical practice in Buenos Aires, Argentina. J Int Assoc Physicians AIDS Care 2010;9(5):306-312. [http:// dx.doi.org/10.1177/1545109710376250]
20. Edwards SG, Larbalestier N, Hay P, et al. Experience of nevirapine use in a London cohort of HIV-infected pregnant women. HIV Med 2001;2:89-91. [http://dx.doi.org/10.1046/j.1468-1293.2001.00059.x]
21. Joao EC, Calvet GA, Menezes JA, et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol 2006;194:199-202. [http://dx.doi.org/10.1016/j.ajog.2005.05.015]
22. Kramer F, Stek A, Du WB, et al. Nevirapine tolerability in HIV-infected women in pregnancy. 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004, San Francisco (CA).
23. Manfredi R, Calza L. Safety issues about nevirapine administration in HIV-infected pregnant women. J Acquir Immune Defic Syndr 2007;45(3):365-368. [http://dx.doi.org/10.1097/QAI.0b013e318050d879]
24. Ouyang DW, Shapiro DE, Lu M, et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS 2009;23(18):2425-2430. [http://dx.doi.org/10.1097/QAD.0b013e32832e34b1]
25. Timmermans S, Tempelman C, Godfried MH, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS 2005;19(8):795-799.
26. Weinberg A, Forster-Harwood J, Davies J, et al. Safety and tolerability of antiretrovirals during pregnancy. Infect Dis Obstet Gynecol 2011;e867674. [http://dx.doi.org/10.1155/2011/867674]
27. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy. Results from PACTG 1022. J Acquir Immune Defic Syndr 2004;36(3):772-776.
28. Natarajan U, Pym A, McDonald C, et al. Safety of nevirapine in pregnancy. HIV Med 2007;8:64-69. [http://dx.doi.org/10.1111/j.1468-1293.2007.00433.x]
29. Peters PJ, Polle N, Zeh C, et al. Nevirapine-associated hepatotoxicity and rash among HIVinfected pregnant women in Kenya. J Int Assoc Physicians AIDS Care 2011; [http://dx.doi. org/10.1177/1545109711423445]
30. Aaron E, Kempf M, Criniti S, et al. Adverse events in a cohort of HIV infected pregnant and nonpregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. PLoS ONE 2010;5(9):e12617. [http://dx.doi.org/10.1371/journal.pone.0012617]
31. Coffie PA, Tonwe-Gold B, Tanon AK, et al. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Cote d'Ivoire. BMC Infect Dis 2010;10:188. [http://dx.doi.org/10.1186/1471-2334-10-188]
32. Gonzales-Garcia A, Fernandez MI, Cotter A. Nevirapine toxicity in the obstetrical population when used in combination of other antiretrovirals. The XV International AIDS Conference, 11-16 July 2004, Bangkok, Thailand.
33. Jamisse L, Balkus J, Hitti J, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007;44(4):371-376. [http://dx.doi.org/10.1097/QAI.0b013e318032bbee]
34. Joy S, Poi M, Hughes L, et al. Third trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol 2005;106(5):1032-1038. [http://dx.doi.org/10.1097/01.AOG.0000180182.00072.e3]
35. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus Study. J Acquir Immune Defic Syndr 2009;52(3):406-416. [http://dx.doi.org/10.1097/ QAI.0b013e3181b323ff]
36. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006;7:255-260. [http://dx.doi.org/10.1111/j.1468-1293.2006.00369.x]
37. Phanuphak N, Apornpong T, Teeratakulpisarn S, et al. Nevirapine-associated toxicity in HIVinfected Thai men and women, including pregnant women. HIV Med 2007;8:357-366. [http://dx.doi. org/10.1111/j.1468-1293.2007.00477.x]
38. van Schalkwyk JE, Alimenti A, Khoo D, et al. Serious toxicity associated with continuous nevirapinebased HAART in pregnancy. BJOG 2008;115:1297-1302. [http://dx.doi.org/10.1111/j.1471-0528.2008.01820.x]
39. Mocroft A, Staszewski S, Weber R, et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and-experienced HIV-infected patients with high and low CD4 T-cell counts. Antivir Ther 2007;12:325-333.
40. De Lazzari E, Leon A, Arnaiz JA, et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med 2008;9:221-226. [http://dx.doi.org/10.1111/j.1468-1293.2008.00552.x]
41. Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008;22(4):540-541. [http://dx.doi.org/10.1097/ QAD.0b013e3282f37812]
42. Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007;21(2):264-265. [http://dx.doi.org/10.1097/QAD.0b013e32801199d9]
43. Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an adult AIDS Clinical Trials Group Collaboration. Clin Infect Dis 2006;43:783-786. [http://dx.doi. org/10.1058-4838/2006/4306-0021]
44. McKoy JM, Bennett CL, Scheetz MH, et al. Hepatotoxicity associated with long-versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug Events And Reports (RADAR) project. Drug Saf 2009;32(2):147-158. [http://dx.doi. org/10.2165/00002018-200932020-00007]